ijms-logo

Journal Browser

Journal Browser

Advances in Lupus Erythematosus and Lupus Nephritis: Pathogenesis, Biomarkers and Treatments

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 403

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medicine, Tuen Mun Hospital, Tsing Chung Koon Road, New Territories, Hong Kong
Interests: systemic lupus erythematosus; particularly lupus nephritis; rheumatoid arthritis; glucocorticoid induced osteoporosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the availability of new immunomodulatory therapies, the survival of systemic lupus erythematosus (SLE) has failed to improve since the mid-1990s. Today, the need to develop novel management strategies for SLE that incorporate a better balance of efficacy and toxicity has yet to be met. 

These strategies include the earlier recognition of major organ manifestations, such as lupus nephritis (LN), early aggressive therapies for high-risk patients to minimize organ damage, the better monitoring of disease activity, maintenance therapies to reduce disease flares, and the enhancement of medication adherence. The ultimate goal of SLE therapy is to induce and maintain a long-lasting remission, minimize organ damage and treatment-related complications, and to improve quality of life. 

This Special Issue of “Advances in Lupus Erythematosus and Lupus Nephritis: Pathogenesis, Biomarkers and Treatments“ in International Journal of Molecular Science (IJMS) covers works in different research areas of SLE. We welcome original articles, clinical trials, laboratory works, reviews, and meta-analyses. 

Topics of interest include, but are not limited to, the following:

  1. Genomic, transcriptomic, and metabolomic studies of systemic lupus erythematosus/ lupus nephritis (SLE/LN);
  2. Classification criteria;
  3. Disease activity indices;
  4. Organ damage and comorbidities;
  5. Serological, urine, and tissue biomarkers for the prediction of SLE/LN prognosis and flares;
  6. Novel therapeutic modalities and strategies for SLE and LN.

Prof. Dr. Chi Chiu Mok
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lupus erythematosus
  • lupus nephritis
  • SLE
  • LN
  • organ damage
  • pathogenesis
  • biomarkers
  • genomic
  • transcriptomic
  • metabolomic
  • treatments
  • therapeutic

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

12 pages, 622 KiB  
Review
The Potential Use of Arsenic Trioxide in the Treatment of Systemic Lupus Erythematosus
by Tsz Ching Mok and Chi Chiu Mok
Int. J. Mol. Sci. 2024, 25(17), 9577; https://doi.org/10.3390/ijms25179577 - 4 Sep 2024
Viewed by 265
Abstract
Arsenic trioxide (ATO) is now part of the standard regimen for the treatment of newly diagnosed and relapsed acute promyelocytic leukemia. The availability of an oral form of ATO has greatly reduced the incidence of cardiotoxicity as compared to intravenous (IV) administration. Increasing [...] Read more.
Arsenic trioxide (ATO) is now part of the standard regimen for the treatment of newly diagnosed and relapsed acute promyelocytic leukemia. The availability of an oral form of ATO has greatly reduced the incidence of cardiotoxicity as compared to intravenous (IV) administration. Increasing evidence suggests that ATO has anti-inflammatory properties that may be useful for the treatment of autoimmune diseases. These include the modulation of Treg cell activation, Th1/Th2 and Th17/Treg balance, depletion of activated T cells and plasmacytoid dendritic cells, and influence of B-cell differentiation, leading to reduced autoantibody and cytokine production. ATO has also been shown to induce apoptosis of activated fibroblast-like synoviocytes through the generation of reactive oxygen species and alter the gut microbiota in collagen-induced arthritis. Despite the emergence of newer treatment modalities, the treatment of systemic lupus erythematosus (SLE), especially refractory manifestations, remains a challenge, owing to the paucity of effective biological and targeted therapies that are devoid of adverse effects. Oral ATO is an attractive option for the treatment of SLE because of the lower cost of production, convenience of administration, and reduced cardiotoxicity. This article summarizes the anti-inflammatory mechanisms of ATO and its potential application in the treatment of SLE and other rheumatic diseases. Full article
Show Figures

Figure 1

Back to TopTop